Orion Portfolio Solutions LLC Has $1.18 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Orion Portfolio Solutions LLC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 60.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 3,286 shares of the biotechnology company’s stock after acquiring an additional 1,233 shares during the period. Orion Portfolio Solutions LLC’s holdings in United Therapeutics were worth $1,178,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of UTHR. Sequoia Financial Advisors LLC acquired a new stake in United Therapeutics in the 2nd quarter worth about $205,000. Wealth Enhancement Advisory Services LLC raised its stake in United Therapeutics by 3.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 2,666 shares of the biotechnology company’s stock worth $849,000 after purchasing an additional 81 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in United Therapeutics in the 2nd quarter worth about $306,000. Blue Trust Inc. raised its stake in United Therapeutics by 41.7% in the 2nd quarter. Blue Trust Inc. now owns 968 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 285 shares in the last quarter. Finally, Raymond James & Associates raised its stake in United Therapeutics by 25.8% in the 2nd quarter. Raymond James & Associates now owns 35,142 shares of the biotechnology company’s stock worth $11,194,000 after purchasing an additional 7,211 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $361.81 on Friday. The firm has a 50 day moving average price of $369.94 and a two-hundred day moving average price of $342.19. The stock has a market cap of $16.15 billion, a P/E ratio of 15.89, a price-to-earnings-growth ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.38 earnings per share. Analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on UTHR shares. Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This represents a 85.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 119,340 shares of company stock worth $44,765,530 over the last three months. Company insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.